What Deprenon Treats: Main Uses and Benefits

Deprenon may be considered relevant for easing symptoms associated with conditions that involve disruptive emotional and behavioral manifestations. Its use may be relevant in contexts involving heightened systemic burden and fluctuating symptom patterns. The medication is commonly used to treat several key psychiatric conditions.

The therapeutic benefit of Deprenon is commonly used across domains where additional symptomatic support is needed, primarily in Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Bulimia Nervosa, and Premenstrual Dysphoric Disorder (PMDD). It helps address symptom clusters that may become intense or disruptive, such as persistent low mood, unwanted thoughts, and sudden episodes of fear. By assisting with managing symptom intensity, it provides supportive relief that may help patients cope more steadily with symptom fluctuations.

“It is commonly used to help with symptom management in conditions presenting with acute or recurrent episodes of distress.”

---

Quick Fact: Relief for Compulsive Behaviors

This medication is commonly used to help with symptoms when they intensify, and may be applied in addressing the distressing manifestations of unwanted thoughts (obsessions) and the need to perform ritualistic actions (compulsions) in OCD. These applications support the patient during difficult episodes by easing distress and may assist with maintaining functional stability.

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Deprenon? Official Regulatory Information

Deprenon (Fluoxetine) eligibility is determined by specific regulatory criteria defined in official prescribing information, focusing on contraindications, age, and patient status.

---

Contraindicated Populations (Must Not Use)

Category	Regulatory Status
Concomitant Drug Use	Contraindicated with Monoamine Oxidase Inhibitors (MAOIs), Pimozide, and Thioridazine. A mandatory five-week washout period is required after stopping Deprenon before an MAOI can be started.
Hypersensitivity	Contraindicated in patients with a known hypersensitivity to the active ingredient (fluoxetine) or any component.

---

Age and Condition Restrictions

Category	Eligibility Rule
Age (Adult)	Approved for all listed adult indications (18 years and older).
Age (Pediatric)	Approved for Major Depressive Disorder in patients ge 8 years and Obsessive-Compulsive Disorder in patients ge 7 years. Safety is not established below these ages.
Hepatic Impairment	Use is conditional in patients with liver cirrhosis and other hepatic impairments, requiring special consideration due to altered clearance.
Pregnancy/Lactation	Use during pregnancy is permitted only if the potential benefit justifies the potential risks to the fetus. Breastfeeding is not recommended.

The regulatory profile mandates caution in patients with a history of seizures or those predisposed to heart rhythm abnormalities (QT prolongation).

The interaction profile for Deprenon, whose active ingredient is Fluoxetine hydrochloride, is defined by strict regulatory prohibitions and documented metabolic effects.

Prohibited Combinations and Timing Rules

Co-administration is contraindicated with certain substances, including Monoamine Oxidase Inhibitors (MAOIs), Linezolid, Intravenous Methylene Blue, Pimozide, and Thioridazine. The contraindication with MAOIs is due to the risk of serious adverse reactions, while the prohibition with Pimozide and Thioridazine is related to the potential for QT interval prolongation. Regulatory requirements establish mandatory timing separation: a washout period of at least 14 days is required before starting Deprenon after an MAOI, and at least 5 weeks after stopping Deprenon before initiating an MAOI.

---

Pharmacokinetic and Pharmacodynamic Interactions

Pharmacokinetically, Deprenon is documented as a potent inhibitor of the CYP2D6 enzyme pathway. This inhibition can lead to the elevation of plasma concentrations for co-administered medicines metabolized by CYP2D6, such as certain Tricyclic Antidepressants, antipsychotics, and anticonvulsants. Pharmacodynamically, co-administration with other serotonergic agents or the herbal product St. John’s Wort increases the documented risk of Serotonin Syndrome. Additionally, combining Deprenon with anti-hemostatic agents, such as NSAIDs or Warfarin, may potentiate the risk of bleeding. Deprenon can be administered with or without food.

Deprenon is a neurosteroid that rapidly crosses the blood-brain barrier to exert its effects primarily within the central nervous system.

Its core biological target is the gamma-aminobutyric acid type A ( GABA A) receptor complex, an ionotropic chloride channel responsible for mediating inhibitory neurotransmission. Deprenon functions as a positive allosteric modulator of this receptor.

The interaction involves binding at sites distinct from the endogenous GABA ligand-binding site, specifically at the interface of the alpha and beta subunits of the GABA A receptor. By allosterically modifying the receptor conformation, Deprenon increases the frequency and/or duration of the chloride channel opening when GABA is bound.

This action enhances the influx of chloride ions ( Cl^-) into the postsynaptic neuron, which consequently hyperpolarizes the neuronal membrane. This increase in GABA-mediated inhibitory signaling leads to a net reduction in neuronal excitability, particularly in extrasynaptic receptors, which mediate tonic inhibitory currents.

The downstream cascade involves the acute dampening of excitatory neurotransmission across relevant neural circuits, resulting in system-level physiological modulation characterized by reduced overall central nervous system network activity.

How to Use Deprenon: Official Administration Guidelines

Deprenon is administered intravenously for patients in whom oral administration of related valproate products is temporarily not feasible, typically for seizure control (epilepsy). This injectable formulation is intended for short-term use, generally not exceeding 14 days. The dosage and administration must be precisely calculated and closely monitored by a healthcare professional.

---

Dosing and Route

Administration Factor	Official Instruction
Route of Administration	Intravenous (IV) use only.
Dosing Schedule	Individualized; an initial dose of 10 to 15 mg/kg/day is typically used for adults and children 10 years and older.
Dose Titration	The daily dose is generally increased by 5 to 10 mg/kg/day at weekly intervals to achieve the best clinical response.
Maximum Dose	The maximum recommended dose is 60 mg/kg/day.

---

Procedural and Timing Rules

• Infusion Rate: Deprenon must be administered as a 60-minute infusion, with the rate not exceeding 20 mg/min.
• Frequency and Timing: The drug should be administered with the same frequency as the oral valproate products it is replacing (e.g., twice or three times daily). The infusion timing should be maintained consistently.
• Age-Specific Rule: For complex partial seizures, the dosage recommendations apply to adults and children 10 years of age or older.
• Preparation: Prior to administration, Deprenon (Valproate Sodium Injection, 100 mg/mL) must be visually inspected, and care must be taken to administer it immediately after preparation.
• Missed Dose: Instructions for missed doses are not typically provided for a professionally administered intravenous product, as it is given under medical supervision in a clinical setting.
• Switching: Patients must be transitioned to an oral valproate product as soon as clinically feasible, as the intravenous use is strictly temporary.

Deprenon: Recent Clinical Evidence

Evidence for Core Indications

The research examining Deprenon has been conducted through numerous short-term Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses across its core studied indications. For Major Depressive Disorder (MDD), research explored how symptoms change over time by observing changes in symptom severity in adults, geriatric patients, and youth. For Obsessive-Compulsive Disorder (OCD), studies examined populations measuring the reduction in the frequency and severity of obsessive and compulsive symptoms using the Y-BOCS scale. Research for Bulimia Nervosa (BN) and Premenstrual Dysphoric Disorder (PMDD) was evaluated using controlled trials that monitored core behavioral and physical symptom outcomes, respectively, over defined periods. Acute treatment trials typically monitor symptom evolution over 8 to 12 weeks.

---

Long-term Studies and Follow-up

Research has explored long-term use through extension and maintenance trials, focusing primarily on recurrence outcomes. For MDD, research examined outcomes related to recurrence over periods up to one year. Conversely, for OCD and PMDD, limited information is available regarding the long-term maintenance of measured changes in symptoms. Findings describe group patterns, not personal outcomes, and evidence for the effects of treatment extending over many years is not fully established across all indications.

---

Evidence in Special Populations and Uncertainties

Studies have examined outcomes in geriatric patients and youth for MDD and in pediatric populations for OCD. Evidence quality varies in youth populations, with some research reporting changes that were modest when compared to control groups. A key area of uncertainty is that the majority of RCTs have had limited follow-up durations. Comparative evidence is lacking for certain groups, and data for severe or complex subgroups remain insufficient, highlighting what is still uncertain about the overall evidence landscape.

Key Studies & References

1. Short- and Long-Term Antidepressant Clinical Trials for Major Depressive Disorder in Youth: Findings and Concerns (Including long-term follow-up and relapse rates)
2. WHO EML Review: Fluoxetine - obsessive-compulsive disorder (OCD) and comparison to other SSRIs

Common questions about Deprenon (FAQ)

Q: How long does it take for Deprenon to start working?

Studies and official information indicate that acute treatment trials for conditions like Major Depressive Disorder (MDD) typically monitor symptom changes over periods of 8 to 12 weeks. This timeframe is generally used to assess the full clinical response. Some individuals may notice initial changes earlier than this.

Q: How long is the washout period after stopping Deprenon before I can start an MAOI?

Regulatory requirements establish mandatory timing separation due to the risk of serious interaction. According to the official product information, a washout period of at least 5 weeks (35 days) is required after stopping Deprenon before initiating a Monoamine Oxidase Inhibitor (MAOI).

Q: What are the most common side effects of Deprenon?

The official safety profile categorizes adverse effects by incidence rate. Very common adverse reactions, occurring in 1 in 10 patients or more, include Nausea, Diarrhea, Insomnia, and Headache. Regulatory documents list several other reactions as Common, which occur in less than 1 in 10 patients.

Q: What is the mechanism of action of the oral forms of Deprenon?

Deprenon is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). The mechanism of action is understood to involve selectively inhibiting the reuptake of the neurotransmitter serotonin in the brain. This action helps to modulate the concentration of active serotonin in the neuronal spaces.

Q: What should I do if I miss a dose of Deprenon?

Regulatory patient information often provides general instructions regarding missed doses. This guidance typically advises against taking a missed dose if it is almost time for the next scheduled dose, and recommends against taking a double dose to compensate for the single missed dose. These instructions should be reviewed with a healthcare provider.

Q: What should I do if I overdose on Deprenon?

Official labeling states that an overdose is a serious medical emergency and requires prompt professional attention. The labeling identifies possible symptoms of overdose, which may include agitation, fever, confusion, and irregular heart rhythm. Anyone who suspects an overdose should immediately contact emergency services.

Q: How is Deprenon different from an older antidepressant like a tricyclic?

Deprenon belongs to the SSRI class, which is a distinct pharmacological category from older antidepressants, such as tricyclic antidepressants (TCAs). Regulatory reviews suggest that Deprenon is typically associated with a different side-effect profile compared to TCAs. This difference is often noted in relation to effects like anticholinergic effects.

Q: What should I do if I get a rash while taking Deprenon?

Official product information notes that allergic reactions and rash have been documented. Labeling contains a specific warning that discontinuation of Deprenon may be necessary if a rash develops whose underlying cause cannot be determined. This information is intended primarily for the prescribing healthcare provider.

Q: What dosage of Deprenon is used for OCD?

Official regulatory prescribing information defines the dosing parameters for Obsessive-Compulsive Disorder (OCD), including typical starting doses and the maximum daily dose. The specific dosage for any individual patient is determined and adjusted by a healthcare professional based on clinical status.

How to Store and Dispose of Deprenon

Official regulatory documents define strict requirements for storing and disposing of Deprenon (selegiline hydrochloride) to maintain its stability and ensure environmental safety.

---

Storage Requirements

• Temperature: Store at controlled room temperature, between 20 C and 25 C.
• Environment: Keep the medicine in its original container, tightly closed, and protect it from excess heat and moisture.
• Safety: The medication must be stored out of the reach of children.

---

Disposal Instructions

• In-Use Stability: For oral disintegrating tablets, any unused medicine must be discarded 3 months after the protective foil pouch is opened.
• Environmental Safety: Because the compound is a potential hazard to the aquatic environment, unused or expired Deprenon must not be disposed of via household trash or wastewater. Disposal must be conducted in accordance with local, regional, and national collection systems for hazardous waste.